Impact of extent of lymphadenectomy on survival, post neoadjuvant chemotherapy and transthoracic esophagectomy

Annals of Surgery

Volumn 265, Issue 4, 2017, Pages 750-756

  Phillips, Alexander W ^a   Lagarde, Sjoerd M ^b   Navidi, Maziar ^a   Disep, Babbet ^a   Griffin, S Michael ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

adenocarcinoma; esophageal cancer; esophagectomy; lymphadenectomy

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN; FLUOROURACIL; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BIOPSY; COMPUTER ASSISTED TOMOGRAPHY; ENDOSCOPIC ULTRASONOGRAPHY; ENDOSCOPY; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; GASTROESOPHAGEAL JUNCTION; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; SURVIVAL RATE; AGED; CANCER STAGING; COHORT ANALYSIS; DISEASE FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; EVALUATION STUDY; FACTUAL DATABASE; KAPLAN MEIER METHOD; MORTALITY; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SURGERY; SURVIVAL ANALYSIS; THORACOTOMY; TREATMENT OUTCOME; TUMOR INVASION;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; THORACOTOMY; TREATMENT OUTCOME;

EID: 84980000622     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001737     Document Type: Article

References (39)

1. Arnold M, Soerjomataram I, Ferlay J, et a.l. Global incidence of oesophageal cancer by histological subtype in. Gut. 2012; 64: 381-387
2. Dubecz A, Gall I, Solymosi N, et a.l. Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis. J Thorac Oncol. 2012; 7: 443-447
3. Altorki N, Kent M, Ferrara C, et a.l. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg. 2002; 236: 177-183
4. Portale G, Hagen JA, Peters JH, et a.l. Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients. J Am Coll Surg. 2006; 202: 588-596
5. Kutup A, Nentwich MF, Bollschweiler E, et a.l. What should be the gold standard for the surgical component in the treatment of locally advanced esophageal cancer: transthoracic versus transhiatal esophagectomy. Ann Surg. 2014; 260: 1016-1022
6. Davies AR, Gossage JA, Zylstra J, et a.l. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction. J Clin Oncol. 2014; 32: 2983-2990
7. Stein HJ, Von Rahden BHA, Siewert JR. Survival after oesophagectomy for cancer of the oesophagus. Langenbecks Arch Surg. 2005; 390: 280-285
8. Bogoevski D, Onken F, Koenig A, et a.l. Is it time for a new TNM classification in esophageal carcinoma? Ann Surg. 2008; 247: 633-641
9. Kelty CJ, Kennedy CW, Falk GL. Ratio of metastatic lymph nodes to total number of nodes resected is prognostic for survival in esophageal carcinoma. J Thorac Oncol. 2010; 5: 1467-1471
10. Hu Y, Hu C, Zhang H, et a.l. How does the number of resected lymph nodes influence TNM staging and prognosis for esophageal carcinoma? Ann Surg Oncol. 2010; 17: 784-790
11. Darling G. The role of lymphadenectomy in esophageal cancer. J Surg Oncol. 2009; 99: 189-193
12. Boshier PR, Anderson O, Hanna GB. Transthoracic versus transhiatal esophagectomy for the treatment of esophagogastric cancer: a meta-analysis. Ann Surg. 2011; 254: 894-906
13. Davies AR, Sandhu H, Pillai A, et a.l. Surgical resection strategy and the influence of radicality on outcomes in oesophageal cancer. Br J Surg. 2014; 101: 511-517
14. Allum WH, Blazeby JM, Griffin SM, et a.l. Guidelines for the management of oesophageal and gastric cancer. Gut. 2011; 60: 1449-1472
15. Rizk NP, Ishwaran H, Rice TW, et a.l. Optimum lymphadenectomy for esophageal cancer. Ann Surg. 2010; 251: 46-50
16. Talsma AK, Ong C-AJ, Liu X, et a.l. Location of lymph node involvement in patients with esophageal adenocarcinoma predicts survival. World J Surg. 2014; 38: 106-113
17. Talsma AK, Shapiro J, Looman CWN, et a.l. Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival. Ann Surg. 2014; 260: 786-792
18. Veeramachaneni NK, Zoole JB, Decker PA, et a.l. Lymph node analysis in esophageal resection: American College of Surgeons Oncology Group Z0060 trial. Ann Thorac Surg. 2008; 86: 418-421
19. Van Der Schaaf M, Johar A, Wijnhoven B, et a.l. Extent of lymph node removal during esophageal cancer surgery and survival. J Natl Cancer Inst. 2015; 5: 107
20. Lagergren J, Mattsson F, Zylstra J, et a.l. Extent of lymphadenectomy and prognosis after esophageal cancer surgery. JAMA Surg. 2015; 1-8
21. Omloo JMT, Lagarde SM, Hulscher JBF, et a.l. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus. Ann Surg. 2007; 246: 992-1001
22. McK Manson J, Beasley WD A personal perspective on controversies in the surgical management of oesophageal cancer. Ann R Coll Surg Engl. 2014; 96: 575-578
23. TNM Classification of Malignant Tumours, 7th Edition [Internet]. Sobin, LH. Wiley-Blackwell; 2009. Available at: http://eu.wiley.com/WileyCDA/Wiley-Title/productCd-1444332414.html
24. Allum WH, Stenning SP, Bancewicz J, et a.l. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009; 27: 5062-5067
25. Cunningham D, Allum WH, Stenning SP, et a.l. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355: 11-20
26. Cunningham D, Starling N, Rao S, et a.l. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008; 358: 36-46
27. Griffin SM, Shaw IH, Dresner SM. Early complications after Ivor Lewis subtotal esophagectomy with two-field lymphadenectomy: risk factors and management. J Am Coll Surg. 2002; 194: 285-297
28. Mapstone N. Dataset for the Histopathological Reporting of Oesophageal Carcinoma. 2nd ed, London: The Royal College of Pathologists; 2007
29. Hosch S, Kraus J, Scheunemann P, et a.l. Malignant potential and cytogenetic characteristics of occult disseminated tumor cells in esophageal cancer. Cancer Res. 2000; 60: 6836-6840
30. Izbicki JR, Hosch SB, Pichlmeier U, et a.l. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med. 1997; 337: 1188-1194
31. Glickman JN, Torres C, Wang HH, et a.l. The prognostic significance of lymph node micrometastasis in patients with esophageal carcinoma. Cancer. 1999; 85: 769-778
32. Vazquez-Sequeiros E, Wang L, Burgart L, et a.l. Occult lymph node metastases as a predictor of tumor relapse in patients with node-negative esophageal carcinoma. Gastroenterology. 2002; 122: 1815-1821
33. De Bekker-Grob EW, Niers EJ, Van Lanschot JJB, et a.l. Patients preferences for surgical management of esophageal cancer: a discrete choice experiment. World J Surg. 2015; 39: 2492-2499
34. Grotenhuis BA, Wijnhoven BPL, van Marion R, et a.l. The sentinel node concept in adenocarcinomas of the distal esophagus and gastroesophageal junction. J Thorac Cardiovasc Surg. 2009; 138: 608-612
35. Patti MG. Survival after lymphadenectomy in patients with esophageal cancer: a controversial issue. JAMA Surg. 2016; 151: 40
36. Markar SR, Wiggins T, Ni M, et a.l. Assessment of the quality of surgery within randomised controlled trials for the treatment of gastro-oesophageal cancer: a systematic review. Lancet Oncol. 2015; 16: e23-e31
37. Cichowitz A, Burton P, Brown W, et a.l. Ex vivo dissection increases lymph node yield in oesophagogastric cancer. ANZ J Surg. 2015; 85: 80-84
38. Lagarde SM, Reitsma JB, De Castro SMM, et a.l. Prognostic nomogram for patients undergoing oesophagectomy for adenocarcinoma of the oesophagus or gastro-oesophageal junction. Br J Surg. 2007; 94: 1361-1368
39. Choi AH, Kim J, Chao J. Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond. World J Gastroenterol. 2015; 21: 7343-7348